A New Treatment Option for Patients with Complex Peripheral Artery Disease (PAD) Now Available at Cheyenne Regional Medical Center

March 6, 2026 – Cheyenne Regional is excited to announce a new treatment option for patients with complex Peripheral Artery Disease (PAD). By offering Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System, our team of experts can provide another option for patients with long lesions in their superficial femoral artery (SFA). We are proud to bring this innovative technology to our community and look forward to helping patients with complex PAD.

The DETOUR System, which earned Breakthrough Device Designation from the FDA in 2020 and recently received approval from the FDA in June 2023, is designed specifically for patients with severe PAD in the superficial femoral artery (SFA). These patients include those who have long obstructions in the SFA, those with previously failed endovascular procedures, and those who may not be good candidates for surgical bypass.
The development of the DETOUR System has been guided by data, including two multicenter, international studies. Clinical evidence demonstrates PTAB, using the DETOUR System, is an effective treatment option for patients with long complex SFA disease.

“Our hospital is committed to providing the latest treatment options for our patients with PAD,” said Tim Thornell, President and CEO at Cheyenne Regional. “We are excited to offer PTAB with the DETOUR System, which can help provide an alternative treatment option for patients.”